SOPHiA GENETICS SA (NASDAQ:SOPH) Sees Large Increase in Short Interest

SOPHiA GENETICS SA (NASDAQ:SOPH) saw a large growth in short interest during the month of February. As of February 13th, there was short interest totaling 226,049 shares, a growth of 194.3% from the January 29th total of 76,808 shares. Currently, 0.4% of the shares of the company are sold short. Based on an average trading volume of 258,111 shares, the short-interest ratio is currently 0.9 days. Based on an average trading volume of 258,111 shares, the short-interest ratio is currently 0.9 days. Currently, 0.4% of the shares of the company are sold short.

Analyst Ratings Changes

SOPH has been the topic of several research analyst reports. Guggenheim boosted their price target on SOPHiA GENETICS from $6.00 to $7.00 and gave the company a “buy” rating in a research note on Monday, January 26th. Wall Street Zen raised SOPHiA GENETICS to a “hold” rating in a report on Saturday, November 1st. Weiss Ratings reiterated a “sell (d-)” rating on shares of SOPHiA GENETICS in a research report on Thursday, January 22nd. Finally, BTIG Research increased their price target on shares of SOPHiA GENETICS from $6.00 to $7.00 and gave the stock a “buy” rating in a report on Monday, November 10th. Two analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, SOPHiA GENETICS has a consensus rating of “Hold” and an average target price of $7.00.

SOPHiA GENETICS Stock Down 0.7%

SOPH stock opened at $4.57 on Friday. SOPHiA GENETICS has a one year low of $2.58 and a one year high of $5.70. The company has a debt-to-equity ratio of 0.78, a quick ratio of 2.62 and a current ratio of 2.80. The firm’s fifty day moving average is $4.93 and its 200 day moving average is $4.39. The firm has a market cap of $308.84 million, a PE ratio of -9.93 and a beta of 1.11.

Institutional Inflows and Outflows

Large investors have recently made changes to their positions in the business. XTX Topco Ltd acquired a new stake in SOPHiA GENETICS in the 4th quarter valued at $55,000. Quadrature Capital Ltd purchased a new stake in shares of SOPHiA GENETICS during the fourth quarter worth about $54,000. Archon Capital Management LLC raised its position in shares of SOPHiA GENETICS by 3.4% during the 4th quarter. Archon Capital Management LLC now owns 441,413 shares of the company’s stock worth $2,061,000 after purchasing an additional 14,342 shares during the last quarter. Renaissance Technologies LLC lifted its stake in SOPHiA GENETICS by 169.5% in the 4th quarter. Renaissance Technologies LLC now owns 83,000 shares of the company’s stock valued at $388,000 after buying an additional 52,200 shares in the last quarter. Finally, Polen Capital Management LLC acquired a new stake in SOPHiA GENETICS in the 4th quarter worth about $102,000. 31.59% of the stock is owned by institutional investors and hedge funds.

SOPHiA GENETICS Company Profile

SOPHiA GENETICS SA is a data-driven medicine company founded in 2011 and headquartered in La Tène, Switzerland. The firm develops and operates a cloud-native software platform designed to standardize and analyze complex genomic and radiomic data. Its core offering, the SOPHiA DDM™ platform, leverages artificial intelligence and machine learning algorithms to help healthcare institutions, laboratories and biopharmaceutical partners derive actionable insights from next-generation sequencing and medical imaging datasets.

The SOPHiA DDM™ platform supports a range of clinical applications, including oncology, hereditary diseases and rare genetic disorders.